EUVIMEDEUVIMED entdecken
Crossref

A case of autoimmune hemolytic anemia that developed four years after initiation of pembrolizumab for recurrent maxillary gingival carcinoma

Tomohiro ABE, Takuji YASUDA, Takasuke USUKI, Masato MINOHARA, Susumu TANAKA, Hideo YOSHIOKA

Japanese Journal of Oral and Maxillofacial Surgery · 18.09.2026 · 72 (9) · 559-566

DOI: 10.5794/jjoms.72.559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Oral and Maxillofacial Surgery, erschienen am 18.09.2026. Verfasst von Tomohiro ABE und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pembrolizumab is an immune checkpoint inhibitor (ICI) that exerts its antitumor effect by inhibiting the binding of PD-1 to PD-L1 or PD-L2, which occurs between cancer cells and T cells, and thereby activating tumor-specific cytotoxic T cells. ICIs are known to cause immune-related adverse events (irAE) such as interstitial pneumonia, enteritis, liver dysfunction, hypothyroidism, and peripheral neuropathy. Autoimmune hemolytic anemia (AIHA) is quite rare; here we report a case of severe AIHA caused by long-term treatment with pembrolizumab, which improved with steroid pulse therapy. A 76-year-old man with a right maxillary gingival carcinoma underwent a hemimaxillectomy and right radical neck dissection; however, the disease recurred and pembrolizumab was initiated. In the fourth year after starting the therapy, jaundice was observed on the skin and eyelid conjunctiva. Blood tests showed an Hb level of 5.9g/dL, haptoglobin under 10mg/dL, total bilirubin of 5.5mg/dL, and a positive Coombs test. Under the diagnosis of AIHA associated with pembrolizumab administration, the patient started steroid pulse therapy. After the treatment was found to be effective without serious side effects, the steroid dose was tapered off and the patient was discharged on the 42nd hospital day. Although reports of AIHA triggered by pembrolizumab rechallenge are rare, making it a potential option for managing the tumor, further studies are needed due to the limited number of documented cases.

Zitieren

APA

ABE, T., YASUDA, T., USUKI, T., MINOHARA, M., TANAKA, S., & YOSHIOKA, H. (2026). A case of autoimmune hemolytic anemia that developed four years after initiation of pembrolizumab for recurrent maxillary gingival carcinoma. Japanese Journal of Oral and Maxillofacial Surgery, 72(9), 559-566. https://doi.org/10.5794/jjoms.72.559

Vancouver

ABE T, YASUDA T, USUKI T, MINOHARA M, TANAKA S, YOSHIOKA H. A case of autoimmune hemolytic anemia that developed four years after initiation of pembrolizumab for recurrent maxillary gingival carcinoma. Japanese Journal of Oral and Maxillofacial Surgery. 2026;72(9):559-566. doi:10.5794/jjoms.72.559

BibTeX
@article{ABE2026,
  author = {ABE, Tomohiro and YASUDA, Takuji and USUKI, Takasuke and MINOHARA, Masato and TANAKA, Susumu and YOSHIOKA, Hideo},
  title = {A case of autoimmune hemolytic anemia that developed four years after initiation of pembrolizumab for recurrent maxillary gingival carcinoma},
  journal = {Japanese Journal of Oral and Maxillofacial Surgery},
  year = {2026},
  volume = {72},
  number = {9},
  pages = {559--566},
  doi = {10.5794/jjoms.72.559}
}
Kostenlos starten →